US20090233329A1 - Microfluidic chamber assembly for mastitis assay - Google Patents
Microfluidic chamber assembly for mastitis assay Download PDFInfo
- Publication number
- US20090233329A1 US20090233329A1 US12/294,037 US29403707A US2009233329A1 US 20090233329 A1 US20090233329 A1 US 20090233329A1 US 29403707 A US29403707 A US 29403707A US 2009233329 A1 US2009233329 A1 US 2009233329A1
- Authority
- US
- United States
- Prior art keywords
- base
- wedge
- milk
- chamber
- edge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000004396 mastitis Diseases 0.000 title claims abstract description 28
- 238000003556 assay Methods 0.000 title claims description 24
- 210000004027 cell Anatomy 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 18
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 235000013336 milk Nutrition 0.000 claims description 58
- 239000008267 milk Substances 0.000 claims description 58
- 210000004080 milk Anatomy 0.000 claims description 58
- 239000007788 liquid Substances 0.000 claims description 12
- 239000003086 colorant Substances 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000006651 lactation Effects 0.000 claims description 6
- 230000000284 resting effect Effects 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 4
- 230000000712 assembly Effects 0.000 claims 1
- 238000000429 assembly Methods 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 abstract description 8
- 239000010839 body fluid Substances 0.000 abstract description 6
- 239000012530 fluid Substances 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 238000001514 detection method Methods 0.000 abstract description 3
- 239000002356 single layer Substances 0.000 abstract description 2
- 235000020247 cow milk Nutrition 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 11
- 239000004033 plastic Substances 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 238000013461 design Methods 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000010817 Wright-Giemsa staining Methods 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000031462 Bovine Mastitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZOMLUNRKXJYKPD-UHFFFAOYSA-N 1,3,3-trimethyl-2-[2-(2-methylindol-3-ylidene)ethylidene]indole;hydrochloride Chemical compound [Cl-].C1=CC=C2C(C)(C)C(/C=C/C=3C4=CC=CC=C4NC=3C)=[N+](C)C2=C1 ZOMLUNRKXJYKPD-UHFFFAOYSA-N 0.000 description 1
- PHWHSHNIIPVVHF-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-ethyliminocyclohexa-2,5-dien-1-ylidene)methyl]-n,n-diethyl-2-methylaniline;hydrochloride Chemical compound Cl.C1=CC(=NCC)C=CC1=C(C=1C=C(C)C(N(CC)CC)=CC=1)C1=CC=C(N)C=C1 PHWHSHNIIPVVHF-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- UYQVPCFMVWEDCA-UHFFFAOYSA-M [6-(diethylamino)-9-[2-[[9-(diethylamino)benzo[a]phenoxazin-5-ylidene]carbamoyl]phenyl]xanthen-3-ylidene]-diethylazanium;chloride Chemical compound [Cl-].C12=CC=CC=C2C2=NC3=CC=C(N(CC)CC)C=C3OC2=CC1=NC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 UYQVPCFMVWEDCA-UHFFFAOYSA-M 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000013184 decreased milk production Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- PKALEBFTSZCHGU-UHFFFAOYSA-M n,n-diethyl-4-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]aniline;chloride Chemical compound [Cl-].C1=CC(N(CC)CC)=CC=C1\C=C\C1=[N+](C)C2=CC=CC=C2C1(C)C PKALEBFTSZCHGU-UHFFFAOYSA-M 0.000 description 1
- ZTBANYZVKCGOKD-UHFFFAOYSA-M n-(2-chloroethyl)-n-methyl-4-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]aniline;chloride Chemical compound [Cl-].C1=CC(N(CCCl)C)=CC=C1C=CC1=[N+](C)C2=CC=CC=C2C1(C)C ZTBANYZVKCGOKD-UHFFFAOYSA-M 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 238000002810 primary assay Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- G01N15/1433—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/02—Food
- G01N33/04—Dairy products
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1484—Electro-optical investigation, e.g. flow cytometers microstructural devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/2813—Producing thin layers of samples on a substrate, e.g. smearing, spinning-on
-
- G01N2015/016—
Definitions
- the present invention relates to microfluidic chamber for analyzing a subjects' body fluids, in particular milk, to determine if the subject has a bacterial infection such as bovine mastitis.
- the invention relates to a chamber assembly which can be used to detect mastitis or other bacterial disease in bovine or other mammal species.
- Mastitis is the inflammation of the mammary gland caused by microorganisms that invade one or more quadrants of the bovine udder, multiply, and produce toxins that are harmful to the mammary gland. Economic loss to mastitis in the United States is estimated to be approximately $185/cow annually. The total annual US cost of mastitis is over $ 2 billion. This is approximately 10% of the total value of farm milk sales, and about two-thirds of this loss is due to reduced milk production in subclinically infected cows.
- the average production loss per lactation for one infected udder quarter is about 1,600 pounds. Other losses are due to discarded abnormal milk and milk withheld from cows treated with antibiotic, costs of early replacement of affected cows, reduced sale value of culled cows, costs of drugs and veterinary services, and increased labor costs. Mastitis reduces milk yield and alters milk composition. The magnitude of these changes in individual cows varies with the severity and duration of the infection and the causative microorganisms. Mastitis is almost always caused by bacteria. These microorganisms produce toxins that can directly damage milk-producing tissue of the mammary gland, and the presence of bacteria initiates inflammation within the mammary tissue in an attempt to eliminate the invading microorganisms. The inflammation contributes to decreased milk production and is primarily responsible for the compositional changes observed in milk from infected quarters and cows. In general, compositional changes involve an increase in blood components present in milk and a decrease in normal milk constituents.
- Clinical Mastitis includes visible signs of mastitis such as the “mild” signs, for example, flakes or clots in the milk, or slight swelling of an infected quarter. It also includes “severe” signs such as abnormal secretion; hot, swollen quarter or full udder; fever, rapid pulse, loss of appetite; dehydration and depression; and in some cases death may occur.
- Subclinical Mastitis there are no visible signs of the disease. Diagnosis of sublinical mastitis is characterized by the Somatic Cell Count (SCC) of the milk being elevated and the bacteriological culturing of milk will detect bacteria in the milk. Subclinical mastitis causes the greatest financial loss to dairy farmers through lowered milk production. For every clinical case of clinical mastitis, there will be 15 to 40 sub-clinical cases.
- SCC Somatic Cell Count
- the SCC is the number of leukocytes or white blood cells per milliliter of milk.
- the SCC has become the standard procedure for diagnosing sub-clinical mastitis and is also used worldwide as the index of milk quality.
- the SCC enumerates the many cells that populate the milk-producing gland as part of the immune defense system, and then cross the blood/milk barrier, as well as the few epithelial cells that line the udder, and also get into the milk.
- the animals' immune systems produce an “inflammatory response” in the gland and more of the infection-fighting white cells (mostly neutrophils) find their way into the milk.
- the SCC is reported as “the sum”, the total of those cells. Normal milk will have less than 200,000 cells per milliliter.
- SCC 200,000 and over
- SCC is the current measure for commercial acceptability for milk in many countries, for example milk with an SCC over 400,000 can not be sold in Europe. Other countries limits include Canada, 500,000 and the United States 750,000 (600,000 in California). Currently there is no SCC associated with Clinical Mastitis.
- the SCC is also used in bulk tank management, in determining the suitability for shipment, in making culling decisions and in the payment of quality bonuses.
- the SCC a single number, is everywhere in the dairy industry and it is used in almost every area of milk production.
- the SCC led to increases in productivity, losses due to clinical-stage mastitis being stabilized, and the generally accepted notion that the milk supply is safe.
- the SCC is not a number representing a single type of leucocyte, rather it is a mixture of multiple types of leukocytes, each with its own significance.
- the predominant cell types are lymphocytes, followed by much lesser numbers of neutrophils and macrophages.
- the percentages of each kind of cell rise and fall as part of the immune response to infection. Those percentages, “the differential milk leukocyte count”, represent the unique immune status of an individual quarter udder, at a specific point in time.
- the literature has suggested that a better understanding of the dynamics of mastitis could be accomplished by specifically measuring the rise and fall in the types of leukocytes involved in the disease process and recovery.
- the literature has also specifically identified the normal differential pattern of uninfected cows at various stages of lactation, it has suggested algorithms to identify the various stages of infection by looking at changes in those patterns and it has suggested linkages of specific abnormal patterns to specific pathogens.
- Hamman used the differential pattern to show quarters were inter-dependent.
- the literature suggests that the breakdown of the SCC into its component parts, the “milk somatic cell differential”, should be a better, more accurate and specific indicator of udder health, and thus a better tool for the management of mastitis.
- the SCC continues to be reported as a total SCC, and the differential information remains a research tool. This is primarily been driven by the cost differential between the SCC and computations for a differential.
- milk is centrifuged at 2500 g for 10 min at 4 degrees Celsius, the fat layer and supernatant are removed, leaving 500 ul or less of milk with a pellet.
- the pellet is re-suspended via vortexing and pipetting.
- Microscope slides are coated with Trypticase Soy Broth, air-dried and 10 ul of milk is placed on the slide for a 30-degree angle smear to be made. The slide is allowed to air dry and is then stained with Wright Giemsa Stain. The slide is placed in the stain for 15 seconds, then water for 30 seconds, then a 15 second dip in clean water and finally it is allowed to air dry. Slides are examined on a transmitted light microscope with a 100 ⁇ oil immersion lens.
- FIG. 1 is a wedge type slide comprising a microscope slide base, a slip cover wedge top and a rectilinear shim at the top part of the wedge.
- This design is described primarily for blood but is taught to be useful for any leucocyte containing liquid for example milk.
- the device suffers from some difficulties in use. First since the cover slip end opposite the shim is not fixed the end can leak, shift or get caught on other objects during use. Second since the design involves a shim the entire length of the cover slip there is no easy way to place the liquid in the chamber.
- FIG. 2 in the Wardlaw patent describes the appropriate angle for creating a wedge sampling configuration for us in differential testing. Accordingly, it would be very useful to have a different wedge chamber design that overcomes the limitations of the prior art teachings.
- the assay itself comprises in one embodiment, method for performing a leukocyte differential assay comprising:
- FIG. 1 shows an embodiment of the invention with a dual chamber mounted on a base.
- FIG. 2 displays enhanced images produced by an embodiment of the invention.
- FIG. 3 displays graphs of the resultant cell count produced by an embodiment of the present invention.
- the present invention relates to a novel microfluidic wedge chamber and a leucocyte differential assay (LDA) for determination if a subject has mastitis in a given sample of milk.
- LDA leucocyte differential assay
- the general description of both the device and method are stated in the Brief Summary above. This detailed description defines the meaning of the terms used herein and specifically describes embodiments in order for those skilled in the art to practice the invention.
- the assay is done exposing leucocyte containing body fluid such as bovine milk, whole blood or other leucocyte containing body fluid such as lymph fluid, spinal fluid or the like, to a predetermined cell count in the device of the invention.
- the test is compared for difference in leucocyte types and those differences determine if the subject has mastitis i.e.
- leucocyte SCC is 200,000 or greater and what the breakdown of different leucocytes within that population is.
- a distinct advantage of the assay of the invention is that it is not only qualitative in nature, it is quantitative in nature and therefore leucocyte such measurements are more telling of the exact condition of the subject bovine patient.
- subject is meant herein to be any animal especially bovine and especially bovine milk containing leucocytes. I addition other birds, mammals and especially humans, that have body fluids containing leucocytes.
- the primary assay of the invention is use of the chamber to test for bovine mastitis but the chamber could simply be used to make a leucocyte determination for other bodily fluids for example as taught in the Wardlaw patent described above.
- leucocyte is meant any of the sub categories of leucocytes that are known to exist in milk or blood or other bodily fluid. These sub-categories can be identified and quantified with the device and assay of the invention especially for the detection of mastitis or other leucocyte based disease states.
- the base is meant a substrate sufficient for performing a leucocyte differential determination.
- the base would be a microscope slide made of glass or plastic and optionally optically transparent. It is clear however that where the determination is made with observation and lighting from the top of the assembly, that the base could be a non-transparent material such as paper or opaque plastic.
- Wild top is meant a substrate which forms the angle top wall of a chamber such as described in Wardlaw.
- top portion is a slide cover slip of glass or plastic which is positioned to form a wedge chamber for making cell count differential determinations. It is an embodiment that the wedge top be optically transparent but where a reading is taken from the bottom the top may be opaque and be of a material other than plastic or glass including paper cardboard, metal or the like.
- wedge forming device is meant a device which by its design accomplishes 4 important functions. First, it secures an edge of the wedge top to the base. Second, it secures the opposite edge of the top in an elevated configuration such that the wedge shaped chamber is formed sufficient for cell differential determination. One skilled in the art as taught above would easily be able to determine the proper angles for such chamber. Third, it secures the opposite side in such a manner that it may not move during normal use and fourthly, it provides a cut-out well so that liquid may be added to the top portion of the wedge instead of from the side as in previous prior art wedge chambers. This is accomplished by use of an adhesive backed film in one embodiment.
- the adhesive film is cut out in such a manner that a flap for adhesion of one side of the top is formed.
- the film also has a cut out portion allowing for an unobstructed view of the top and base. Further it provides a means for securing the top edge of the top and it also provides a cut out portion for a liquid addition well.
- the wedge configuration of the chamber is then formed by one edge of the top resting against the base and the other opposite edge of the top resting on the film, the thickness of the film determines the shape and volume of the chamber. In general, where the base is a microscope slide and the top a slide slip cover the film would be chosen to be about 0.04 to 0.06 mm more or less in thickness. In one embodiment, the film is 0.05 mm in thickness.
- the adhesive allows the film to be attached to the base and the top simultaneously because of the adhesive backing and the unique cut-out design.
- the film is in an embodiment a polymer which gives it both flexibility and ease of putting an adhesive backing thereon.
- the adhesive should be such that it adheres to both the top and base and one skilled in the art would be able to make optimum choices depending on the materials chosen for the top and base.
- the liquid in the chamber is observed by methods taught for differentiation (see Example) and thus the chamber allows for differentiation of the leucocyte sub-population.
- deriving a differential count is meant that once the sub populations of the ample are determined that a count of each of the sub populations is made such that the sub population of the total SCC count can be determined.
- Leucocyte observation colorants are compounds known to differentially color morphological factors, in a leucocyte and cause various colorations (spectral factors) at various wavelengths based on the leucocytes reaction or lack of reaction to the antigen.
- Examples of such colorants include but are not limited to: Astrozone Orange, Also known as Basic Orange 21 which is 3-trimethyl-2(2-(2-methyl-1H-indol-3-yl)-vinyl)-3H-indolium chloride.
- colorants include Acridine Orange, Ethidium Bromide, Griefswalder's Blue, Blue Borrel, Rhodanile Blue, Toluidine Blue, Night Blue, Prune Pure, Hofmann's Violet, Basic Red 13, Basic Violet 16, Carbocyanine K-5, and mixtures of above.
- Many of the colorants are cytotoxic. When selecting a cytotoxic colorant it is preferable to allow it to be in contact with cells the minimum time. In the embodiment of the invention where the observation and reaction chambers are separate the minimum time in contact is achieved. Where the predetermined time is short enough or the colorant is not cytotoxic the embodiment where the reaction and observation microchambers of each test are the same microchamber can be used.
- the “chamber” is a chamber for which leucocytes measurement factors can easily be observed by optical scan.
- The is designed to spread out the fluid sample in such a manner to make a field by field, YYZ scan possible. See, for example, U.S. Pat. No. 6,350,613 which describes such chamber and optical scan thereby.
- the device is made in a disposable format.
- This device would be made of plastic, glass or other inexpensive disposable material.
- the device of the invention containing the subject sample can be discarded in an appropriate manner and the tester need never come in contact with the contents.
- the disposable microfluidic device can be constructed credit card size more or less similar to other microfluidic assays such that it fits in a reader portion of an image analyzer that can read the colorimetric data from the tests by either moving the test device around or moving a reader in the analyzer or both to take readings of the type in the above referenced patents and also described herein. A microscopic slide size will also be useful.
- FIG. 1 is an embodiment of the invention wherein two wedge chambers are shown suitable for two assays.
- the microfluidic assembly 1 consists of the wedge base 2 , which in this case is a microscopic glass slide. Other materials including plastics can be used for the wedge base 2 Wedge base 2 is shown as a rectangle but one skilled in the art could chose what ever shape necessary or desired to accommodate the assay or assay machine.
- the Wedge base 2 is a microscope slide.
- a slide is a good embodiment since slides are readily available in both glass and plastic and normally come optically transparent.
- FIG. 1 there are actually two Microfluidic chambers since based on the size of the chambers it is easy to place multiple chambers on the base 2 .
- the wedge top 6 in this embodiment is a microscope slide slip cover and has a first edge 15 and an opposite second edge 16 .
- Thin glass is used in this embodiment but plastic and other thicknesses as desired could be substituted as well.
- the wedge forming device 8 is a piece of cut out plastic sheeting with an adhesive backing facing the wedge base 2 .
- the wedge forming device 8 is placed against the base 2 so that it adheres.
- the functioning of the wedge forming device 8 will be clear now upon looking at this embodiment.
- the scored hold down flap 20 adheres to the top 6 and holds the first edge 15 securely against the base 2 forming the bottom point of a chamber 30 .
- the second opposite edge 16 rests on the upper surface of the wedge forming device 8 such that it forms the high point under the top 6 of chamber 30 .
- the top 6 is held down in place on the upper surface of wedge forming device 8 by two arms 35 which fold over the top and adhere to the tops upper surface.
- a last feature in the wedge forming device 8 is a cut out for a liquid addition well 38 .
- a liquid for example bovine milk is placed in well 38 and spreads out evenly in chamber 30 .
- the design of the chamber is such that at the first end of the top the area under the top is such that a single layer of cells is created within chamber 30 .
- 80 ⁇ l of milk is mixed with 20 ⁇ l of a meta-chromatic stain, gently mixed, and a small drop of the mixture is placed in the deposition well of a slide of the invention.
- the wedge of the slide chamber fills automatically by capillary action, the cells in the milk are distributed evenly at optimum locations, and are ready for observation in seconds.
- a pre-concentration step may be required for very low SCC samples.
- the wedge can be aptly described as a “self preparing wet smear.”
- the enhanced imaged is analyzed using mathematical features captured by software derived from face-recognition/machine-vision research, and a report of the percent of each of the three inflammatory cells is presented, as well as total SCC.
- the dark areas are % PMN, the light areas are % lymphocytes and the cross hatched areas are % macrophages.
- SCC is ⁇ 1000 cells/ml for all examples. See FIG. 3 .
Abstract
Description
- This application claims priority of U.S. provisional patent application No. 60/785,877 filed on 24 Mar. 2006 incorporated herein by reference in its entirety.
- 1. Field of the Invention
- The present invention relates to microfluidic chamber for analyzing a subjects' body fluids, in particular milk, to determine if the subject has a bacterial infection such as bovine mastitis. Specifically, the invention relates to a chamber assembly which can be used to detect mastitis or other bacterial disease in bovine or other mammal species.
- 2. Description of the Related Art
- Mastitis is the inflammation of the mammary gland caused by microorganisms that invade one or more quadrants of the bovine udder, multiply, and produce toxins that are harmful to the mammary gland. Economic loss to mastitis in the United States is estimated to be approximately $185/cow annually. The total annual US cost of mastitis is over $ 2 billion. This is approximately 10% of the total value of farm milk sales, and about two-thirds of this loss is due to reduced milk production in subclinically infected cows.
- The average production loss per lactation for one infected udder quarter is about 1,600 pounds. Other losses are due to discarded abnormal milk and milk withheld from cows treated with antibiotic, costs of early replacement of affected cows, reduced sale value of culled cows, costs of drugs and veterinary services, and increased labor costs. Mastitis reduces milk yield and alters milk composition. The magnitude of these changes in individual cows varies with the severity and duration of the infection and the causative microorganisms. Mastitis is almost always caused by bacteria. These microorganisms produce toxins that can directly damage milk-producing tissue of the mammary gland, and the presence of bacteria initiates inflammation within the mammary tissue in an attempt to eliminate the invading microorganisms. The inflammation contributes to decreased milk production and is primarily responsible for the compositional changes observed in milk from infected quarters and cows. In general, compositional changes involve an increase in blood components present in milk and a decrease in normal milk constituents.
- Clinical Mastitis includes visible signs of mastitis such as the “mild” signs, for example, flakes or clots in the milk, or slight swelling of an infected quarter. It also includes “severe” signs such as abnormal secretion; hot, swollen quarter or full udder; fever, rapid pulse, loss of appetite; dehydration and depression; and in some cases death may occur.
- In Subclinical Mastitis there are no visible signs of the disease. Diagnosis of sublinical mastitis is characterized by the Somatic Cell Count (SCC) of the milk being elevated and the bacteriological culturing of milk will detect bacteria in the milk. Subclinical mastitis causes the greatest financial loss to dairy farmers through lowered milk production. For every clinical case of clinical mastitis, there will be 15 to 40 sub-clinical cases.
- The SCC is the number of leukocytes or white blood cells per milliliter of milk. The SCC has become the standard procedure for diagnosing sub-clinical mastitis and is also used worldwide as the index of milk quality. The SCC enumerates the many cells that populate the milk-producing gland as part of the immune defense system, and then cross the blood/milk barrier, as well as the few epithelial cells that line the udder, and also get into the milk. In response to infection, the animals' immune systems produce an “inflammatory response” in the gland and more of the infection-fighting white cells (mostly neutrophils) find their way into the milk. The SCC is reported as “the sum”, the total of those cells. Normal milk will have less than 200,000 cells per milliliter. An elevated SCC (200,000 and over) is an indication of inflammation in the udder. The SCC is the current measure for commercial acceptability for milk in many countries, for example milk with an SCC over 400,000 can not be sold in Europe. Other countries limits include Canada, 500,000 and the United States 750,000 (600,000 in California). Currently there is no SCC associated with Clinical Mastitis.
- The SCC is also used in bulk tank management, in determining the suitability for shipment, in making culling decisions and in the payment of quality bonuses. In summary, the SCC, a single number, is everywhere in the dairy industry and it is used in almost every area of milk production. The SCC led to increases in productivity, losses due to clinical-stage mastitis being stabilized, and the generally accepted notion that the milk supply is safe.
- The SCC is not a number representing a single type of leucocyte, rather it is a mixture of multiple types of leukocytes, each with its own significance. In milk from a healthy animal, the predominant cell types are lymphocytes, followed by much lesser numbers of neutrophils and macrophages. The percentages of each kind of cell rise and fall as part of the immune response to infection. Those percentages, “the differential milk leukocyte count”, represent the unique immune status of an individual quarter udder, at a specific point in time. The literature has suggested that a better understanding of the dynamics of mastitis could be accomplished by specifically measuring the rise and fall in the types of leukocytes involved in the disease process and recovery. The literature has also specifically identified the normal differential pattern of uninfected cows at various stages of lactation, it has suggested algorithms to identify the various stages of infection by looking at changes in those patterns and it has suggested linkages of specific abnormal patterns to specific pathogens. In 2005, Hamman used the differential pattern to show quarters were inter-dependent. Essentially, the literature suggests that the breakdown of the SCC into its component parts, the “milk somatic cell differential”, should be a better, more accurate and specific indicator of udder health, and thus a better tool for the management of mastitis. However, in spite of the evolving evidence, the SCC continues to be reported as a total SCC, and the differential information remains a research tool. This is primarily been driven by the cost differential between the SCC and computations for a differential.
- At least two procedures are currently used in the determination of the bovine SCC with a leucocyte differential. One method is using flow-cytometry, an expensive, sophisticated tool only found in top research laboratories. This method is not even remotely practical for the farmer. Its only alternative, the “manual milk differential smear” (MMDS), is a difficult and time consuming procedure, subject to great variability, even when performed by highly trained laboratory technologists. It is impractical for field research or the barn environment as well.
- In order to perform an MMDS, milk is centrifuged at 2500 g for 10 min at 4 degrees Celsius, the fat layer and supernatant are removed, leaving 500 ul or less of milk with a pellet. The pellet is re-suspended via vortexing and pipetting. Microscope slides are coated with Trypticase Soy Broth, air-dried and 10 ul of milk is placed on the slide for a 30-degree angle smear to be made. The slide is allowed to air dry and is then stained with Wright Giemsa Stain. The slide is placed in the stain for 15 seconds, then water for 30 seconds, then a 15 second dip in clean water and finally it is allowed to air dry. Slides are examined on a transmitted light microscope with a 100× oil immersion lens.
- In U.S. Pat. No. 6,350,613 to Wardlaw, there is described a device and method for determination of white blood cell differential counts. The slide described in
FIG. 1 is a wedge type slide comprising a microscope slide base, a slip cover wedge top and a rectilinear shim at the top part of the wedge. This design is described primarily for blood but is taught to be useful for any leucocyte containing liquid for example milk. The device suffers from some difficulties in use. First since the cover slip end opposite the shim is not fixed the end can leak, shift or get caught on other objects during use. Second since the design involves a shim the entire length of the cover slip there is no easy way to place the liquid in the chamber. -
FIG. 2 in the Wardlaw patent describes the appropriate angle for creating a wedge sampling configuration for us in differential testing. Accordingly, it would be very useful to have a different wedge chamber design that overcomes the limitations of the prior art teachings. - It is an object of the invention to provide both an assay and a novel microfluidic slide assembly using the wedge design that can be used to test leucocyte containing body fluids such as bovine milk for a leucocyte differential test. It is an object to make the test and slide useful for the farmer in the field and easy enough for a farmer to do or at least prepare. The test is relatively quick, easy to do, accurate, wherein the slide is disposable. The farmer can do the test in the field and use very small volumes of milk. The above objectives and more are achieved by the present invention and are distinct novel advantages as can be further seen from the disclosure herein.
- One embodiment of the device is microfluidic chamber assembly for use in performing leucocyte differential assay on a leucocyte containing fluid sample from a subject in a wedge sampling configuration chamber comprising:
-
- a) an wedge base;
- b) a wedge top forming the angle part of the wedge;
- c) a wedge forming device which secures a first edge of the top to the base forms the bottom edge of the wedge chamber, elevates and secures the opposite second edge of the top from the base to form a wedge chamber and provides for a liquid entry well for liquid addition to the chamber;
- wherein at least one of the base or top is optically transparent.
- The assay itself comprises in one embodiment, method for performing a leukocyte differential assay comprising:
-
- a) adding a leukocyte containing liquid to the chamber of a slide assembly of
claim 1; - b) enumerating and calculating the leucocytes in the liquid containing chamber into sub-populations; and
- c) deriving a differential count of the leucocyte sub-populations.
- a) adding a leukocyte containing liquid to the chamber of a slide assembly of
- Other embodiments and variations will be obvious from the disclosure, teachings and examples herein.
-
FIG. 1 shows an embodiment of the invention with a dual chamber mounted on a base. -
FIG. 2 displays enhanced images produced by an embodiment of the invention. -
FIG. 3 displays graphs of the resultant cell count produced by an embodiment of the present invention. - The present invention relates to a novel microfluidic wedge chamber and a leucocyte differential assay (LDA) for determination if a subject has mastitis in a given sample of milk. The general description of both the device and method are stated in the Brief Summary above. This detailed description defines the meaning of the terms used herein and specifically describes embodiments in order for those skilled in the art to practice the invention. The assay is done exposing leucocyte containing body fluid such as bovine milk, whole blood or other leucocyte containing body fluid such as lymph fluid, spinal fluid or the like, to a predetermined cell count in the device of the invention. The test is compared for difference in leucocyte types and those differences determine if the subject has mastitis i.e. if the leucocyte SCC is 200,000 or greater and what the breakdown of different leucocytes within that population is. A distinct advantage of the assay of the invention is that it is not only qualitative in nature, it is quantitative in nature and therefore leucocyte such measurements are more telling of the exact condition of the subject bovine patient.
- By “subject” is meant herein to be any animal especially bovine and especially bovine milk containing leucocytes. I addition other birds, mammals and especially humans, that have body fluids containing leucocytes. The primary assay of the invention is use of the chamber to test for bovine mastitis but the chamber could simply be used to make a leucocyte determination for other bodily fluids for example as taught in the Wardlaw patent described above.
- By “leucocyte” is meant any of the sub categories of leucocytes that are known to exist in milk or blood or other bodily fluid. These sub-categories can be identified and quantified with the device and assay of the invention especially for the detection of mastitis or other leucocyte based disease states.
- By “wedge base” is meant a substrate sufficient for performing a leucocyte differential determination. In one embodiment the base would be a microscope slide made of glass or plastic and optionally optically transparent. It is clear however that where the determination is made with observation and lighting from the top of the assembly, that the base could be a non-transparent material such as paper or opaque plastic.
- By “Wedge top” is meant a substrate which forms the angle top wall of a chamber such as described in Wardlaw. In one embodiment that top portion is a slide cover slip of glass or plastic which is positioned to form a wedge chamber for making cell count differential determinations. It is an embodiment that the wedge top be optically transparent but where a reading is taken from the bottom the top may be opaque and be of a material other than plastic or glass including paper cardboard, metal or the like.
- By “wedge forming device” is meant a device which by its design accomplishes 4 important functions. First, it secures an edge of the wedge top to the base. Second, it secures the opposite edge of the top in an elevated configuration such that the wedge shaped chamber is formed sufficient for cell differential determination. One skilled in the art as taught above would easily be able to determine the proper angles for such chamber. Third, it secures the opposite side in such a manner that it may not move during normal use and fourthly, it provides a cut-out well so that liquid may be added to the top portion of the wedge instead of from the side as in previous prior art wedge chambers. This is accomplished by use of an adhesive backed film in one embodiment. The adhesive film is cut out in such a manner that a flap for adhesion of one side of the top is formed. The film also has a cut out portion allowing for an unobstructed view of the top and base. Further it provides a means for securing the top edge of the top and it also provides a cut out portion for a liquid addition well. The wedge configuration of the chamber is then formed by one edge of the top resting against the base and the other opposite edge of the top resting on the film, the thickness of the film determines the shape and volume of the chamber. In general, where the base is a microscope slide and the top a slide slip cover the film would be chosen to be about 0.04 to 0.06 mm more or less in thickness. In one embodiment, the film is 0.05 mm in thickness. As can be seen in the figures, the adhesive allows the film to be attached to the base and the top simultaneously because of the adhesive backing and the unique cut-out design. The film is in an embodiment a polymer which gives it both flexibility and ease of putting an adhesive backing thereon. The adhesive should be such that it adheres to both the top and base and one skilled in the art would be able to make optimum choices depending on the materials chosen for the top and base.
- In the assay, by “enumerating and calculating” is meant that the liquid in the chamber is observed by methods taught for differentiation (see Example) and thus the chamber allows for differentiation of the leucocyte sub-population. By deriving a differential count” is meant that once the sub populations of the ample are determined that a count of each of the sub populations is made such that the sub population of the total SCC count can be determined.
- “Leucocyte observation colorants” are compounds known to differentially color morphological factors, in a leucocyte and cause various colorations (spectral factors) at various wavelengths based on the leucocytes reaction or lack of reaction to the antigen. Examples of such colorants include but are not limited to: Astrozone Orange, Also known as
Basic Orange 21 which is 3-trimethyl-2(2-(2-methyl-1H-indol-3-yl)-vinyl)-3H-indolium chloride. Other possible colorants include Acridine Orange, Ethidium Bromide, Griefswalder's Blue, Blue Borrel, Rhodanile Blue, Toluidine Blue, Night Blue, Prune Pure, Hofmann's Violet, Basic Red 13,Basic Violet 16, Carbocyanine K-5, and mixtures of above. Many of the colorants are cytotoxic. When selecting a cytotoxic colorant it is preferable to allow it to be in contact with cells the minimum time. In the embodiment of the invention where the observation and reaction chambers are separate the minimum time in contact is achieved. Where the predetermined time is short enough or the colorant is not cytotoxic the embodiment where the reaction and observation microchambers of each test are the same microchamber can be used. - The “chamber” is a chamber for which leucocytes measurement factors can easily be observed by optical scan. The is designed to spread out the fluid sample in such a manner to make a field by field, YYZ scan possible. See, for example, U.S. Pat. No. 6,350,613 which describes such chamber and optical scan thereby.
- In one embodiment of the invention the device is made in a disposable format. This device would be made of plastic, glass or other inexpensive disposable material. The device of the invention containing the subject sample can be discarded in an appropriate manner and the tester need never come in contact with the contents. The disposable microfluidic device can be constructed credit card size more or less similar to other microfluidic assays such that it fits in a reader portion of an image analyzer that can read the colorimetric data from the tests by either moving the test device around or moving a reader in the analyzer or both to take readings of the type in the above referenced patents and also described herein. A microscopic slide size will also be useful.
- Turning now to the figures
FIG. 1 is an embodiment of the invention wherein two wedge chambers are shown suitable for two assays. Themicrofluidic assembly 1 consists of thewedge base 2, which in this case is a microscopic glass slide. Other materials including plastics can be used for thewedge base 2Wedge base 2 is shown as a rectangle but one skilled in the art could chose what ever shape necessary or desired to accommodate the assay or assay machine. In this view theWedge base 2 is a microscope slide. A slide is a good embodiment since slides are readily available in both glass and plastic and normally come optically transparent. In the embodiment inFIG. 1 there are actually two Microfluidic chambers since based on the size of the chambers it is easy to place multiple chambers on thebase 2. However, it is clear that one skilled in the art could place one or depending on their size more than two on thebase 2. Thewedge top 6 in this embodiment is a microscope slide slip cover and has afirst edge 15 and an oppositesecond edge 16. Thin glass is used in this embodiment but plastic and other thicknesses as desired could be substituted as well. - The
wedge forming device 8 is a piece of cut out plastic sheeting with an adhesive backing facing thewedge base 2. Thewedge forming device 8 is placed against thebase 2 so that it adheres. There areextra portions 12 that extend beyond thebase 2. These extra portions can be folded underneath thebase 2 to form a stronger bond to the base2. The functioning of thewedge forming device 8 will be clear now upon looking at this embodiment. The scored hold downflap 20, adheres to the top 6 and holds thefirst edge 15 securely against thebase 2 forming the bottom point of achamber 30. The secondopposite edge 16 rests on the upper surface of thewedge forming device 8 such that it forms the high point under thetop 6 ofchamber 30. The top 6 is held down in place on the upper surface ofwedge forming device 8 by twoarms 35 which fold over the top and adhere to the tops upper surface. A last feature in thewedge forming device 8 is a cut out for a liquid addition well 38. to perform the assay a liquid for example bovine milk is placed in well 38 and spreads out evenly inchamber 30. The design of the chamber is such that at the first end of the top the area under the top is such that a single layer of cells is created withinchamber 30. - In one embodiment of the assay, 80 μl of milk is mixed with 20 μl of a meta-chromatic stain, gently mixed, and a small drop of the mixture is placed in the deposition well of a slide of the invention. The wedge of the slide chamber fills automatically by capillary action, the cells in the milk are distributed evenly at optimum locations, and are ready for observation in seconds. A pre-concentration step may be required for very low SCC samples. The wedge can be aptly described as a “self preparing wet smear.”
- Once the wedge slide has self-prepared, it is ready for immediate analysis by one of three methods:
- (a) Visual identification by direct observation of the various live, intact, fluorescing cells, using a simple fluorescence microscope (for use by the experienced milk researcher); (b) Visual identification of the various cells using computer-enhanced digital camera images in a computer screen (for the use of a laboratory cytology technician) or (c) Automatic counts of the cells by a simple imaging instrument requiring minimum operator training (for use by non-laboratory personnel in the milking barn).
- Multiple fluorescence images at different wavelengths are captured and the resulting “enhanced image” is displayed for easy identification by the lab technician as shown in
FIG. 2 . - In the on-site simple reader version, the enhanced imaged is analyzed using mathematical features captured by software derived from face-recognition/machine-vision research, and a report of the percent of each of the three inflammatory cells is presented, as well as total SCC.
- The variance of result is illustrated by a few examples of the variety of patterns present in cows. The graphs below suggest that not all cows with the same SCC may be assumed to have the same health status, and that the ratio of differential cells may indeed have clinical relevance.
- The dark areas are % PMN, the light areas are % lymphocytes and the cross hatched areas are % macrophages. SCC is ×1000 cells/ml for all examples. See
FIG. 3 . - Visual Identification of Computer-Enhanced Images Vs. Manual Differential Smear
- Composite samples (n=85) from Holstein dairy cows were collected from North Carolina farms. For each milk sample, a smear4 was prepared from an aliquot, using the Wright-Giemsa stain method, and a “one hundred cell differential” was performed using light microscopy. The test method was prepared from a second aliquot and enhanced images were collected. A certified technologist identified one hundred cells from those images. Comparison of results is shown.
-
Correlation of Visual ID vs. One Hundred Cell Smear Neutrophils (PMN) R2 = 0.763 Lymphocytes R2 = 0.786 Macrophages/Epithelial R2 = 0.713 - Quarter samples (n=122) from Holstein dairy cows were collected from North Carolina farms. For each milk sample, a smear was prepared from an aliquot, using the Wright-Giemsa stain method, and a “two hundred cell differential” was performed using light microscopy. The test method was prepared from a second aliquot and enhanced images were collected. The instrument software identified two hundred cells from those images. Comparison of results is shown.
-
Correlation of Instrumented ID vs. Two Hundred Cell Smear Neutrophils (PMN) R2 = 0.794 Lymphocytes R2 = 0.863 Macrophages/Epithelial R2 = 0.724 - The results obtained with this assay match the statistically expected performance when evaluating manual/visual differential leukocyte counting methods, and we therefore conclude there is reasonably good agreement between it and the more difficult milk differential smear. This new method is a tool to help in the routine management of mastitis. Possible applications of the newly available information include: (a) Stage the disease, (b) an indicator for determining whether to culture, (c) an indicator as far as which fully symptomatic clinical cows are likely to get better, (d) an early warning of mastitis in peri-partum or early lactation, (e) differentiate between a high SCC due to lactation and a high SCC due to intra-mammary infection, (f) confirm quarters with mastitis after positive “in-line” conductivity measurement.
-
- 1. Anderson K L, et al. PMN leukocyte function in clinical bovine patients and in cows with or without Staphylococcus aureus mastitis. Vet Res Com1992; 16(2):107-115
- 2. Doboo I R, et al. Use of total and differential somatic cell counts from composite milk samples to detect mastitis in individual cows. Can J Comp Med. 1981; 45 (1): 8-14
- 3. Dosogne H, et al. Differential leukocyte method for bovine low somatic cell count milk. J Dairy Sci. 2003; (3): 828-34
- 4. Dulin A M, et al. Cytospin centrifuge in differential counts of milk somatic cells. J Dairy Sci. 1982; 65: 1247-1251
- 5. Emanuelson U, et al. Potential of differential somatic cell counts as indicators of mastitis in quarter milk samples from dairy cows. Acta Vet Scand 1989; (4): 475-81
- 6. Hamman J, et al. Differential cell count and interdependence of udder quarters, Proceedings IDF Congress on Mastitis and Milk Quality, June 2005
- 7. Kelly M et al. Correlation between bovine somatic cell counts and PMN Leukocyte levels for samples of bulk milk and milk from individual cows, J Dairy Sci 2000; 83:77:619-627
- 8. Kitchen B J. Review of the progress of dairy science bovine mastitis, milk compositional changes and related diagnostic tests. J Dairy Sci 1981; 48:167-188
- 9. Koepke J A, et al. A critical evaluation of the manual/visual differential leukocyte counting method. Blood Cells 1985: 11:173-186
- 10. Leitner G, et al. Milk leucocyte population patterns in bovine udder infection of different aetiology. Journal Vet Med B 2000; 47, 581-589
- 11. Miller R H, et al. Flow cytometric analysis of neutrophils in cow's milk. Am Vet Res 1993; 54:1975-1979
- 12. Paape, M J, et al. Historical perspective on the evolution of the milk somatic cell count. Flem. Vet. J. Suppl., 66:93
- 13. Pillai, S R et al. Application of differential inflammatory cell count as a tool to monitor udder health. J Dairy Sci 2001; 84:1413-1420
- 14. Redelman D. A mastitis monitoring program using the differential inflammatory cell count (DICC) Pages 219-220, Proc 34th Annual Meeting, NMC, 1997
- 15. Rivas, A L, et al. Longitudinal evaluation of bovine mammary gland health status by somatic cell counting, flow cytometry and cytology. 2001; J Vet Diagn Invest 13:399-407
- 16. Rumke C L. Expected Variability in Differential Leukocyte Counting. In John A. Koepke (Ed.), Differential Leukocyte Counting (pp. 39-45). Aspen: CAP 1977
- 17. Schröder A C, et al. The influence of technical factors on differential cell count in milk. J Dairy Research 2005; 72: 153-158
- The previous examples are not intended to be limiting. One skilled in the art would be able to form other cut-outs, make various material choices and be able to apply the novel design to other assays involving cell differential and the like. The disclosure and the claims are therefore not intended to be limiting.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/294,037 US20090233329A1 (en) | 2006-03-24 | 2007-03-26 | Microfluidic chamber assembly for mastitis assay |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78587706P | 2006-03-24 | 2006-03-24 | |
US12/294,037 US20090233329A1 (en) | 2006-03-24 | 2007-03-26 | Microfluidic chamber assembly for mastitis assay |
PCT/US2007/064893 WO2007112332A2 (en) | 2006-03-24 | 2007-03-26 | Microfluidic chamber assembly for mastitis assay |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/064893 A-371-Of-International WO2007112332A2 (en) | 2006-03-24 | 2007-03-26 | Microfluidic chamber assembly for mastitis assay |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/105,662 Continuation US10983104B2 (en) | 2006-03-24 | 2013-12-13 | Microfluidic chamber assembly for mastitis assay |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090233329A1 true US20090233329A1 (en) | 2009-09-17 |
Family
ID=38541833
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/294,037 Abandoned US20090233329A1 (en) | 2006-03-24 | 2007-03-26 | Microfluidic chamber assembly for mastitis assay |
US14/105,662 Active 2027-10-03 US10983104B2 (en) | 2006-03-24 | 2013-12-13 | Microfluidic chamber assembly for mastitis assay |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/105,662 Active 2027-10-03 US10983104B2 (en) | 2006-03-24 | 2013-12-13 | Microfluidic chamber assembly for mastitis assay |
Country Status (5)
Country | Link |
---|---|
US (2) | US20090233329A1 (en) |
EP (1) | EP2005155B1 (en) |
IL (1) | IL194186A (en) |
NZ (1) | NZ571425A (en) |
WO (1) | WO2007112332A2 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110096157A1 (en) * | 2009-10-28 | 2011-04-28 | Alan Marc Fine | Microscopy imaging |
WO2012052046A1 (en) | 2010-10-18 | 2012-04-26 | Foss Analytical A/S | Method for determining a degree of infection |
WO2013192396A1 (en) | 2012-06-20 | 2013-12-27 | Advanced Animal Diagnostics, Inc. | Sample collection and transfer assembly and related methods |
WO2014008352A1 (en) * | 2012-07-03 | 2014-01-09 | Advanced Animal Diagnostics, Inc. | System and method for automated diagnosis |
US20150063652A1 (en) * | 2013-08-30 | 2015-03-05 | Dairy Quality Inc. | Pathogen determination in fluid |
US9052315B2 (en) | 2012-05-09 | 2015-06-09 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
US9075225B2 (en) | 2009-10-28 | 2015-07-07 | Alentic Microscience Inc. | Microscopy imaging |
US9797893B2 (en) | 2013-05-09 | 2017-10-24 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
US9989750B2 (en) | 2013-06-26 | 2018-06-05 | Alentic Microscience Inc. | Sample processing improvements for microscopy |
US10132794B2 (en) | 2015-09-14 | 2018-11-20 | Essenlix Corporation | Device and system for collecting and analyzing vapor condensate, particularly exhaled breath condensate, as well as method of using the same |
US10222383B2 (en) | 2016-01-29 | 2019-03-05 | Advanced Animal Diagnostics, Inc. | Methods and compositions for detecting mycoplasma exposure |
US10324009B2 (en) | 2015-08-10 | 2019-06-18 | Essenlix Corporation | Bio/chemical assay devices and methods for simplified steps, small samples, accelerated speed, and ease-of-use |
US10359614B2 (en) | 2012-07-03 | 2019-07-23 | Advanced Animal Diagnostics, Inc. | Diagnostic apparatus |
US10502666B2 (en) | 2013-02-06 | 2019-12-10 | Alentic Microscience Inc. | Sample processing improvements for quantitative microscopy |
US10605805B2 (en) | 2015-09-14 | 2020-03-31 | Essenlix Corporation | Device and system for analyzing a sample, particularly blood, as well as methods of using the same |
US10628693B2 (en) | 2016-12-21 | 2020-04-21 | Essenlix Corporation | Devices and methods for authenticating a sample and use of the same |
US10807095B2 (en) | 2017-10-26 | 2020-10-20 | Essenlix Corporation | Making and tracking assay card |
US11156606B2 (en) | 2018-01-11 | 2021-10-26 | Essenlix Corporation | Homogeneous assay (II) |
US11237113B2 (en) | 2017-10-26 | 2022-02-01 | Essenlix Corporation | Rapid pH measurement |
US11243201B2 (en) | 2017-08-01 | 2022-02-08 | Essenlix Corporation | Sample collection, holding and assaying |
US20220040687A1 (en) * | 2020-08-06 | 2022-02-10 | KovaDx, Inc. | Diagnostic Systems and Methods for Hemolytic Anemias and Other Conditions |
US11274996B2 (en) | 2017-02-07 | 2022-03-15 | Essenlix Corporation | Compressed open flow assay and use |
US11280706B2 (en) | 2017-08-01 | 2022-03-22 | Essenlix Corporation | Dilution calibration |
US11393561B2 (en) | 2017-10-13 | 2022-07-19 | Essenlix Corporation | Devices and methods for authenticating a medical test and use of the same |
US11510608B2 (en) | 2017-12-14 | 2022-11-29 | Essenlix Corporation | Devices, systems, and methods for monitoring hair |
US11523752B2 (en) | 2017-02-16 | 2022-12-13 | Essenlix Corporation | Assay for vapor condensates |
US11604148B2 (en) | 2017-02-09 | 2023-03-14 | Essenlix Corporation | Colorimetric assays |
US11609224B2 (en) | 2017-10-26 | 2023-03-21 | Essenlix Corporation | Devices and methods for white blood cell analyses |
US11648551B2 (en) | 2017-12-12 | 2023-05-16 | Essenlix Corporation | Sample manipulation and assay with rapid temperature change |
US11725227B2 (en) | 2017-08-01 | 2023-08-15 | Essenlix Corporation | Devices and methods for examining drug effects on microorganisms |
US11885952B2 (en) | 2018-07-30 | 2024-01-30 | Essenlix Corporation | Optics, device, and system for assaying and imaging |
US11883824B2 (en) | 2017-02-09 | 2024-01-30 | Essenlix Corporation | Assay using different spacing heights |
US11927560B2 (en) | 2017-02-08 | 2024-03-12 | Essenlix Corporation | Bio/chemical material extraction and assay |
US11940382B2 (en) | 2017-02-09 | 2024-03-26 | Essenlix Corporation | Assay with amplification |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7794741B2 (en) * | 2007-05-30 | 2010-09-14 | Conopco, Inc. | Enhanced delivery of certain fragrance components from personal care compositions |
US9579651B2 (en) | 2009-12-18 | 2017-02-28 | Abbott Point Of Care, Inc. | Biologic fluid analysis cartridge |
US9199233B2 (en) | 2010-03-31 | 2015-12-01 | Abbott Point Of Care, Inc. | Biologic fluid analysis cartridge with deflecting top panel |
CN103282123B (en) | 2010-12-30 | 2015-05-06 | 艾博特健康公司 | Biologic fluid analysis cartridge with sample handling portion and analysis chamber portion |
EP2748618A1 (en) | 2011-08-24 | 2014-07-02 | Abbott Point of Care Inc. | Biologic fluid sample analysis cartridge |
AU2016298095B2 (en) | 2015-07-29 | 2021-05-06 | Advanced Animal Diagnostics, Inc. | Apparatus for rapid collection of blood from livestock |
CN105154315B (en) * | 2015-09-30 | 2017-12-01 | 重庆大学 | A kind of biofluid experiment flow cavity |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963580A (en) * | 1975-02-10 | 1976-06-15 | Microlife Technics, Inc. | Method for determining the suitability of milk for bacterial fermentation activity |
US4190020A (en) * | 1978-01-03 | 1980-02-26 | Mezogazdasagi Foiskola, Kaposvar | Process and equipment for machine milking to provide sterile milk free from blood and pus |
US4385590A (en) * | 1981-12-11 | 1983-05-31 | Bruce Mortensen | Apparatus for on-site detection of mastitis in milk animals |
US4790640A (en) * | 1985-10-11 | 1988-12-13 | Nason Frederic L | Laboratory slide |
US5116731A (en) * | 1984-12-21 | 1992-05-26 | Boehringer Mannheim Gmbh | Process for the detection of an allergy or an anti-allergic substance |
US5168044A (en) * | 1988-12-22 | 1992-12-01 | University College Dublin | Immunodiagnostic assays for use in the detection and determination of mastitis |
US5302903A (en) * | 1989-05-10 | 1994-04-12 | N.V. Nederlandsche Apparatenfabriek Nedap | Mastitis detector for dairy cattle |
US5306719A (en) * | 1986-07-31 | 1994-04-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof |
US5434082A (en) * | 1990-08-06 | 1995-07-18 | Sanwa Kagaku Kenkyusho Co., Ltd | Early diagnosis of mastitis or garget |
US5480778A (en) * | 1989-04-19 | 1996-01-02 | Levine; Robert A. | Determination of lymphocyte reactivity to specific antigens in blood |
US5550148A (en) * | 1995-06-07 | 1996-08-27 | Zymogenetics, Inc. | PAF synthesis modulators |
US5628964A (en) * | 1995-09-18 | 1997-05-13 | Tassitano; Henry | Mastitis detecting device |
US5637469A (en) * | 1992-05-01 | 1997-06-10 | Trustees Of The University Of Pennsylvania | Methods and apparatus for the detection of an analyte utilizing mesoscale flow systems |
US5660993A (en) * | 1993-02-18 | 1997-08-26 | Biocircuits Corporation | Disposable device in diagnostic assays |
US5792964A (en) * | 1995-01-06 | 1998-08-11 | Maasland N.V. A Dutch Limited Liability Company | Milking system including a milk quantity meter |
US5807684A (en) * | 1994-01-21 | 1998-09-15 | Simmons; Maxine Helen | Mastitis test |
US5849488A (en) * | 1996-02-27 | 1998-12-15 | Oulutech Ltd. | DNA-sequence-based diagnosis of mastitis from a milk sample |
US5948686A (en) * | 1998-03-07 | 1999-09-07 | Robert A. Leuine | Method for performing blood cell counts |
US6004821A (en) * | 1998-03-07 | 1999-12-21 | Levine; Robert A. | Method and apparatus for performing chemical, qualitative, quantitative, and semi-quantitative analyses of a urine sample |
US6038030A (en) * | 1997-01-13 | 2000-03-14 | Maasland N.V. | Method of establishing the presence of specific substances in milk as well as an implement for applying same |
US6073580A (en) * | 1996-07-25 | 2000-06-13 | Siliconform Gmbh & Co. Kg | Automatic milk sorting device |
US6127184A (en) * | 1998-03-07 | 2000-10-03 | Robert A. Levine | Calibration of a whole blood sample analyzer |
US6180314B1 (en) * | 1998-05-27 | 2001-01-30 | Becton, Dickinson And Company | Method for preparing thin liquid samples for microscopic analysis |
US6197538B1 (en) * | 1998-11-12 | 2001-03-06 | Maasland N.V. A Dutch Company | Method of establishing the presence of specific substances in milk and an implement for applying same |
US6235536B1 (en) * | 1998-03-07 | 2001-05-22 | Robert A. Levine | Analysis of quiescent anticoagulated whole blood samples |
US6287771B1 (en) * | 1997-09-10 | 2001-09-11 | Snow Brand Milk Products Co., Ltd. | Method for determining mastitis using keratin and casein which are amplified by primers |
US6297045B1 (en) * | 1998-08-04 | 2001-10-02 | Japan As Represented By National Institute Of Animal Health, Ministry Of Agriculture, Forestry And Fishers, Director General | Mastitis diagnosing apparatus |
US6307362B1 (en) * | 1998-02-17 | 2001-10-23 | Agricultural Instruments Canada Ltd. | Somatic cell analyser |
US6330350B1 (en) * | 1997-05-22 | 2001-12-11 | Korea Institute Of Science And Technology | Method and apparatus for automatically recognizing blood cells |
US6350613B1 (en) * | 1998-03-07 | 2002-02-26 | Belton Dickinson & Co. | Determination of white blood cell differential and reticulocyte counts |
US20020028158A1 (en) * | 1998-03-07 | 2002-03-07 | Wardlaw Stephen C. | Apparatus for analyzing biologic fluids |
US20020054831A1 (en) * | 2000-02-02 | 2002-05-09 | Lely Enterprises Ag,A Swiss Limited Liability Company | Implement for detecting physical abnormalities in milk |
US6479017B2 (en) * | 1996-04-24 | 2002-11-12 | Delaval International Ab | Device for measuring an electrical parameter in the milk |
US20020183600A1 (en) * | 2000-03-31 | 2002-12-05 | Roumiana Tsenkova | Method and apparatus for detecting mastitis by using visual light and/or near infrared lights |
US20020197441A1 (en) * | 2001-03-29 | 2002-12-26 | Ramesh Hariharan | Storage medium for data |
US20040019300A1 (en) * | 2002-07-26 | 2004-01-29 | Leonard Leslie Anne | Microfluidic blood sample separations |
US6723290B1 (en) * | 1998-03-07 | 2004-04-20 | Levine Robert A | Container for holding biologic fluid for analysis |
US6858143B2 (en) * | 2000-11-29 | 2005-02-22 | Giuliano Onali | Apparatus for the biological purification of water containing organic materials and derived products thereof |
US6979550B1 (en) * | 2002-09-05 | 2005-12-27 | Rivas Ariel L | Method for diagnosis of, and determination of susceptibility to bovine mastitis |
US20060024756A1 (en) * | 2002-02-14 | 2006-02-02 | Arjan Tibbe | Methods and algorithms for cell enumeration in low-cost cytometer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6319532A (en) * | 1986-07-11 | 1988-01-27 | Sekisui Chem Co Ltd | Plate for observation |
JPH0833392B2 (en) * | 1988-03-29 | 1996-03-29 | 積水化学工業株式会社 | Specimen preparation method and specimen plate |
JP3662161B2 (en) | 2000-03-01 | 2005-06-22 | ユニ・チャーム株式会社 | Anti-stain sheet with multiple sheets joined |
EP1191325B1 (en) | 2000-03-31 | 2007-12-12 | Japan as represented by President of Kobe University | Method and apparatus for detecting mastitis by using visible light and/or near infrared light |
US6658143B2 (en) | 2002-04-29 | 2003-12-02 | Amersham Biosciences Corp. | Ray-based image analysis for biological specimens |
JPWO2003093834A1 (en) * | 2002-04-30 | 2005-09-08 | アークレイ株式会社 | Analysis tool |
-
2007
- 2007-03-26 WO PCT/US2007/064893 patent/WO2007112332A2/en active Application Filing
- 2007-03-26 NZ NZ571425A patent/NZ571425A/en unknown
- 2007-03-26 US US12/294,037 patent/US20090233329A1/en not_active Abandoned
- 2007-03-26 EP EP07759349.9A patent/EP2005155B1/en active Active
-
2008
- 2008-09-17 IL IL194186A patent/IL194186A/en active IP Right Grant
-
2013
- 2013-12-13 US US14/105,662 patent/US10983104B2/en active Active
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963580A (en) * | 1975-02-10 | 1976-06-15 | Microlife Technics, Inc. | Method for determining the suitability of milk for bacterial fermentation activity |
US4190020A (en) * | 1978-01-03 | 1980-02-26 | Mezogazdasagi Foiskola, Kaposvar | Process and equipment for machine milking to provide sterile milk free from blood and pus |
US4385590A (en) * | 1981-12-11 | 1983-05-31 | Bruce Mortensen | Apparatus for on-site detection of mastitis in milk animals |
US5116731A (en) * | 1984-12-21 | 1992-05-26 | Boehringer Mannheim Gmbh | Process for the detection of an allergy or an anti-allergic substance |
US4790640A (en) * | 1985-10-11 | 1988-12-13 | Nason Frederic L | Laboratory slide |
US5306719A (en) * | 1986-07-31 | 1994-04-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof |
US5168044A (en) * | 1988-12-22 | 1992-12-01 | University College Dublin | Immunodiagnostic assays for use in the detection and determination of mastitis |
US5480778A (en) * | 1989-04-19 | 1996-01-02 | Levine; Robert A. | Determination of lymphocyte reactivity to specific antigens in blood |
US5302903A (en) * | 1989-05-10 | 1994-04-12 | N.V. Nederlandsche Apparatenfabriek Nedap | Mastitis detector for dairy cattle |
US5434082A (en) * | 1990-08-06 | 1995-07-18 | Sanwa Kagaku Kenkyusho Co., Ltd | Early diagnosis of mastitis or garget |
US5637469A (en) * | 1992-05-01 | 1997-06-10 | Trustees Of The University Of Pennsylvania | Methods and apparatus for the detection of an analyte utilizing mesoscale flow systems |
US5660993A (en) * | 1993-02-18 | 1997-08-26 | Biocircuits Corporation | Disposable device in diagnostic assays |
US5807684A (en) * | 1994-01-21 | 1998-09-15 | Simmons; Maxine Helen | Mastitis test |
US5792964A (en) * | 1995-01-06 | 1998-08-11 | Maasland N.V. A Dutch Limited Liability Company | Milking system including a milk quantity meter |
US5550148A (en) * | 1995-06-07 | 1996-08-27 | Zymogenetics, Inc. | PAF synthesis modulators |
US5628964A (en) * | 1995-09-18 | 1997-05-13 | Tassitano; Henry | Mastitis detecting device |
US5849488A (en) * | 1996-02-27 | 1998-12-15 | Oulutech Ltd. | DNA-sequence-based diagnosis of mastitis from a milk sample |
US6479017B2 (en) * | 1996-04-24 | 2002-11-12 | Delaval International Ab | Device for measuring an electrical parameter in the milk |
US6073580A (en) * | 1996-07-25 | 2000-06-13 | Siliconform Gmbh & Co. Kg | Automatic milk sorting device |
US6038030A (en) * | 1997-01-13 | 2000-03-14 | Maasland N.V. | Method of establishing the presence of specific substances in milk as well as an implement for applying same |
US6330350B1 (en) * | 1997-05-22 | 2001-12-11 | Korea Institute Of Science And Technology | Method and apparatus for automatically recognizing blood cells |
US6287771B1 (en) * | 1997-09-10 | 2001-09-11 | Snow Brand Milk Products Co., Ltd. | Method for determining mastitis using keratin and casein which are amplified by primers |
US6307362B1 (en) * | 1998-02-17 | 2001-10-23 | Agricultural Instruments Canada Ltd. | Somatic cell analyser |
US6350613B1 (en) * | 1998-03-07 | 2002-02-26 | Belton Dickinson & Co. | Determination of white blood cell differential and reticulocyte counts |
US6723290B1 (en) * | 1998-03-07 | 2004-04-20 | Levine Robert A | Container for holding biologic fluid for analysis |
US6127184A (en) * | 1998-03-07 | 2000-10-03 | Robert A. Levine | Calibration of a whole blood sample analyzer |
US6004821A (en) * | 1998-03-07 | 1999-12-21 | Levine; Robert A. | Method and apparatus for performing chemical, qualitative, quantitative, and semi-quantitative analyses of a urine sample |
US20020028158A1 (en) * | 1998-03-07 | 2002-03-07 | Wardlaw Stephen C. | Apparatus for analyzing biologic fluids |
US20020055178A1 (en) * | 1998-03-07 | 2002-05-09 | Wardlaw Stephen C. | Apparatus and method for analyzing biologic fluids |
US6235536B1 (en) * | 1998-03-07 | 2001-05-22 | Robert A. Levine | Analysis of quiescent anticoagulated whole blood samples |
US5948686A (en) * | 1998-03-07 | 1999-09-07 | Robert A. Leuine | Method for performing blood cell counts |
US6180314B1 (en) * | 1998-05-27 | 2001-01-30 | Becton, Dickinson And Company | Method for preparing thin liquid samples for microscopic analysis |
US6297045B1 (en) * | 1998-08-04 | 2001-10-02 | Japan As Represented By National Institute Of Animal Health, Ministry Of Agriculture, Forestry And Fishers, Director General | Mastitis diagnosing apparatus |
US6197538B1 (en) * | 1998-11-12 | 2001-03-06 | Maasland N.V. A Dutch Company | Method of establishing the presence of specific substances in milk and an implement for applying same |
US20020054831A1 (en) * | 2000-02-02 | 2002-05-09 | Lely Enterprises Ag,A Swiss Limited Liability Company | Implement for detecting physical abnormalities in milk |
US6493071B2 (en) * | 2000-02-02 | 2002-12-10 | Lely Enerprises A.G. | Implement for detecting physical abnormalities in milk |
US20020183600A1 (en) * | 2000-03-31 | 2002-12-05 | Roumiana Tsenkova | Method and apparatus for detecting mastitis by using visual light and/or near infrared lights |
US6858143B2 (en) * | 2000-11-29 | 2005-02-22 | Giuliano Onali | Apparatus for the biological purification of water containing organic materials and derived products thereof |
US20020197441A1 (en) * | 2001-03-29 | 2002-12-26 | Ramesh Hariharan | Storage medium for data |
US20060024756A1 (en) * | 2002-02-14 | 2006-02-02 | Arjan Tibbe | Methods and algorithms for cell enumeration in low-cost cytometer |
US20040019300A1 (en) * | 2002-07-26 | 2004-01-29 | Leonard Leslie Anne | Microfluidic blood sample separations |
US6979550B1 (en) * | 2002-09-05 | 2005-12-27 | Rivas Ariel L | Method for diagnosis of, and determination of susceptibility to bovine mastitis |
Non-Patent Citations (1)
Title |
---|
Jasper et al., "Acridine Orange Staining for Diagnosis of Mycoplasma bovis Infection in Cow Milk," Journal of Clinical Microbiology, Vol. 20, No. 4, pp. 624-625 (1984). * |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9720217B2 (en) | 2009-10-28 | 2017-08-01 | Alentic Microscience Inc. | Microscopy imaging |
US10866395B2 (en) | 2009-10-28 | 2020-12-15 | Alentic Microscience Inc. | Microscopy imaging |
US10620234B2 (en) | 2009-10-28 | 2020-04-14 | Alentic Microscience Inc. | Microscopy imaging |
US10520711B2 (en) | 2009-10-28 | 2019-12-31 | Alentic Microscience Inc. | Microscopy imaging |
US20110096157A1 (en) * | 2009-10-28 | 2011-04-28 | Alan Marc Fine | Microscopy imaging |
US10345564B2 (en) | 2009-10-28 | 2019-07-09 | Alentic Microscience Inc. | Microscopy imaging |
US11947096B2 (en) | 2009-10-28 | 2024-04-02 | Alentic Microscience Inc. | Microscopy imaging |
US9041790B2 (en) | 2009-10-28 | 2015-05-26 | Alentic Microscience Inc. | Microscopy imaging |
US10900999B2 (en) | 2009-10-28 | 2021-01-26 | Alentic Microscience Inc. | Microscopy imaging |
US9075225B2 (en) | 2009-10-28 | 2015-07-07 | Alentic Microscience Inc. | Microscopy imaging |
US11294160B2 (en) | 2009-10-28 | 2022-04-05 | Alentic Microscience Inc. | Microscopy imaging |
US11635447B2 (en) | 2009-10-28 | 2023-04-25 | Alentic Microscience Inc. | Microscopy imaging |
US10114203B2 (en) | 2009-10-28 | 2018-10-30 | Alentic Microscience Inc. | Microscopy imaging |
WO2012052046A1 (en) | 2010-10-18 | 2012-04-26 | Foss Analytical A/S | Method for determining a degree of infection |
US20130157306A1 (en) * | 2010-10-18 | 2013-06-20 | Foss Analytical A/S | Method for determining a degree of infection |
US9052315B2 (en) | 2012-05-09 | 2015-06-09 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
US9482670B2 (en) | 2012-05-09 | 2016-11-01 | Advanced Animal Diagnostic, Inc. | Rapid detection of analytes in liquid samples |
WO2013192396A1 (en) | 2012-06-20 | 2013-12-27 | Advanced Animal Diagnostics, Inc. | Sample collection and transfer assembly and related methods |
WO2014008282A2 (en) | 2012-07-03 | 2014-01-09 | Advanced Animal Diagnostics, Inc. | Diagnostic apparatus |
US10620190B2 (en) | 2012-07-03 | 2020-04-14 | Advanced Animal Diagnostics, Inc. | Diagnostic apparatus |
US9816982B2 (en) | 2012-07-03 | 2017-11-14 | Advanced Animal Diagnostics, Inc. | Diagnostic apparatus |
WO2014008352A1 (en) * | 2012-07-03 | 2014-01-09 | Advanced Animal Diagnostics, Inc. | System and method for automated diagnosis |
US10359614B2 (en) | 2012-07-03 | 2019-07-23 | Advanced Animal Diagnostics, Inc. | Diagnostic apparatus |
US11598699B2 (en) | 2013-02-06 | 2023-03-07 | Alentic Microscience Inc. | Sample processing improvements for quantitative microscopy |
US10768078B2 (en) | 2013-02-06 | 2020-09-08 | Alentic Microscience Inc. | Sample processing improvements for quantitative microscopy |
US10502666B2 (en) | 2013-02-06 | 2019-12-10 | Alentic Microscience Inc. | Sample processing improvements for quantitative microscopy |
US9797893B2 (en) | 2013-05-09 | 2017-10-24 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
US10809512B2 (en) | 2013-06-26 | 2020-10-20 | Alentic Microscience Inc. | Sample processing improvements for microscopy |
US11874452B2 (en) | 2013-06-26 | 2024-01-16 | Alentic Microscience Inc. | Sample processing improvements for microscopy |
US10746979B2 (en) | 2013-06-26 | 2020-08-18 | Alentic Microscience Inc. | Sample processing improvements for microscopy |
US10459213B2 (en) | 2013-06-26 | 2019-10-29 | Alentic Microscience Inc. | Sample processing improvements for microscopy |
US9989750B2 (en) | 2013-06-26 | 2018-06-05 | Alentic Microscience Inc. | Sample processing improvements for microscopy |
US20150063652A1 (en) * | 2013-08-30 | 2015-03-05 | Dairy Quality Inc. | Pathogen determination in fluid |
US9536304B2 (en) * | 2013-08-30 | 2017-01-03 | Dairy Quality Inc. | Determining pathogens based on an image of somatic cells in a fluid sample |
US10948389B2 (en) | 2015-08-10 | 2021-03-16 | Essenlix Corporation | Bio/chemical assay devices and methods for simplified steps, small samples, accelerated speed, and ease-of-use |
US11385143B2 (en) | 2015-08-10 | 2022-07-12 | Essenlix Corporation | Bio/chemical assay devices and methods for simplified steps, small samples, accelerated speed, and ease-of-use |
US10324009B2 (en) | 2015-08-10 | 2019-06-18 | Essenlix Corporation | Bio/chemical assay devices and methods for simplified steps, small samples, accelerated speed, and ease-of-use |
US11543408B2 (en) | 2015-09-14 | 2023-01-03 | Essenlix Corporation | Device and system for analyzing a sample, particularly blood, as well as methods of using the same |
US10830761B2 (en) | 2015-09-14 | 2020-11-10 | Essenlix Corporation | Device and system for collecting and analyzing vapor condensate, particularly exhaled breath condensate, as well as method of using the same |
US10416151B2 (en) | 2015-09-14 | 2019-09-17 | Essenlix Corporation | Device and system for collecting and analyzing vapor condensate, particularly exhaled breath condensate, as well as method of using the same |
US11415570B2 (en) | 2015-09-14 | 2022-08-16 | Essenlix Corporation | Rapid vapor condensate collection and analysis |
US10605805B2 (en) | 2015-09-14 | 2020-03-31 | Essenlix Corporation | Device and system for analyzing a sample, particularly blood, as well as methods of using the same |
US10132794B2 (en) | 2015-09-14 | 2018-11-20 | Essenlix Corporation | Device and system for collecting and analyzing vapor condensate, particularly exhaled breath condensate, as well as method of using the same |
US10222383B2 (en) | 2016-01-29 | 2019-03-05 | Advanced Animal Diagnostics, Inc. | Methods and compositions for detecting mycoplasma exposure |
US10628693B2 (en) | 2016-12-21 | 2020-04-21 | Essenlix Corporation | Devices and methods for authenticating a sample and use of the same |
US11274996B2 (en) | 2017-02-07 | 2022-03-15 | Essenlix Corporation | Compressed open flow assay and use |
US11796428B2 (en) | 2017-02-07 | 2023-10-24 | Essenlix Corporation | Compressed open flow assay and use |
US11927560B2 (en) | 2017-02-08 | 2024-03-12 | Essenlix Corporation | Bio/chemical material extraction and assay |
US11883824B2 (en) | 2017-02-09 | 2024-01-30 | Essenlix Corporation | Assay using different spacing heights |
US11604148B2 (en) | 2017-02-09 | 2023-03-14 | Essenlix Corporation | Colorimetric assays |
US11940382B2 (en) | 2017-02-09 | 2024-03-26 | Essenlix Corporation | Assay with amplification |
US11523752B2 (en) | 2017-02-16 | 2022-12-13 | Essenlix Corporation | Assay for vapor condensates |
US11280706B2 (en) | 2017-08-01 | 2022-03-22 | Essenlix Corporation | Dilution calibration |
US11725227B2 (en) | 2017-08-01 | 2023-08-15 | Essenlix Corporation | Devices and methods for examining drug effects on microorganisms |
US11243201B2 (en) | 2017-08-01 | 2022-02-08 | Essenlix Corporation | Sample collection, holding and assaying |
US11796538B2 (en) | 2017-08-01 | 2023-10-24 | Essenlix Corporation | Sample collection, holding and assaying |
US11393561B2 (en) | 2017-10-13 | 2022-07-19 | Essenlix Corporation | Devices and methods for authenticating a medical test and use of the same |
US11609224B2 (en) | 2017-10-26 | 2023-03-21 | Essenlix Corporation | Devices and methods for white blood cell analyses |
US11237113B2 (en) | 2017-10-26 | 2022-02-01 | Essenlix Corporation | Rapid pH measurement |
US10807095B2 (en) | 2017-10-26 | 2020-10-20 | Essenlix Corporation | Making and tracking assay card |
US11648551B2 (en) | 2017-12-12 | 2023-05-16 | Essenlix Corporation | Sample manipulation and assay with rapid temperature change |
US11696723B2 (en) | 2017-12-14 | 2023-07-11 | Essenlix Corporation | Devices, systems, and methods for monitoring hair |
US11510608B2 (en) | 2017-12-14 | 2022-11-29 | Essenlix Corporation | Devices, systems, and methods for monitoring hair |
US11156606B2 (en) | 2018-01-11 | 2021-10-26 | Essenlix Corporation | Homogeneous assay (II) |
US11885952B2 (en) | 2018-07-30 | 2024-01-30 | Essenlix Corporation | Optics, device, and system for assaying and imaging |
US20220040687A1 (en) * | 2020-08-06 | 2022-02-10 | KovaDx, Inc. | Diagnostic Systems and Methods for Hemolytic Anemias and Other Conditions |
Also Published As
Publication number | Publication date |
---|---|
EP2005155B1 (en) | 2021-06-30 |
EP2005155A4 (en) | 2014-03-19 |
WO2007112332A2 (en) | 2007-10-04 |
NZ571425A (en) | 2011-09-30 |
EP2005155A2 (en) | 2008-12-24 |
IL194186A (en) | 2012-10-31 |
WO2007112332A3 (en) | 2007-11-15 |
US20140315242A1 (en) | 2014-10-23 |
US10983104B2 (en) | 2021-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10983104B2 (en) | Microfluidic chamber assembly for mastitis assay | |
Chien et al. | Urine sediment examination: a comparison of automated urinalysis systems and manual microscopy | |
Lamchiagdhase et al. | Urine sediment examination: a comparison between the manual method and the iQ200 automated urine microscopy analyzer | |
Hannemann-Pohl et al. | Automation of urine sediment examination: a comparison of the Sysmex UF-100 automated flow cytometer with routine manual diagnosis (microscopy, test strips, and bacterial culture) | |
Brito et al. | Andrology laboratory review: Evaluation of sperm concentration | |
US6852527B2 (en) | Apparatus and method for the measurement of cells in biological samples | |
EP2240765A1 (en) | A milk analysis microfluidic apparatus for detecting mastitis in a milk sample | |
Moon et al. | Application of a new portable microscopic somatic cell counter with disposable plastic chip for milk analysis | |
Bellwood et al. | Veterinary technician's handbook of laboratory procedures | |
Rossi et al. | The effect of inter-laboratory variability on the protein: creatinine (UPC) ratio in canine urine | |
Dimech et al. | Evaluation of an automated urinalysis system for testing urine chemistry, microscopy and culture | |
Berry et al. | Use of the DeLaval cell counter (DCC) on goats' milk | |
CN114047151A (en) | Instrument and detection method for simultaneously carrying out sample analysis and immunity measurement | |
Alves et al. | Preliminary evaluation of the Iris IQ™ 200 automated urine analyser | |
Papakonstantinou et al. | Rapid, effective and user-friendly immunophenotyping of canine lymphoma using a personal flow cytometer | |
NO20130484A1 (en) | PROCEDURE FOR DETERMINING THE DEGREE OF INFECTION | |
Sun et al. | Milk somatic cell count: From conventional microscope method to new biosensor-based method | |
Santoro et al. | Platelet concentrations and platelet‐associated IgG in greyhounds | |
Nakayama et al. | Outline and features of UF-5000, fully automated urine particle analyzer | |
US10718757B2 (en) | Method for the rapid and convenient detection and enumeration of neutrophils in biological samples | |
Cenariu et al. | Advanced techniques of bovine semen analysis. | |
Feng et al. | Comparing techniques for detecting the number of somatic cells in raw milk | |
US20210356487A1 (en) | Multisystem for simultaneously performing biochemical examination and blood test, and multi-disc used therein | |
CN113785185A (en) | Method for optimizing the concentration of target elements for visual measurements of biological samples | |
US20230173482A1 (en) | Urine analysis systems and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADVANCED ANIMAL DIAGNOSTICS, NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RODRIGUEZ, RUDY R;GALANAUGH, CHARLES F;REEL/FRAME:021946/0719;SIGNING DATES FROM 20081125 TO 20081201 |
|
AS | Assignment |
Owner name: ADVANCED ANIMAL DIAGNOSTICS, NORTH CAROLINA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CHANGE ASIGNOR'S NAME FROM RUDY R RODRIGUEZ TO RODOLFO R RODRIGUEZ PREVIOUSLY RECORDED ON REEL 021946 FRAME 0719;ASSIGNORS:RODRIGUEZ, RODOLFO R;GALANAUGH, CHARLES F;REEL/FRAME:022261/0569;SIGNING DATES FROM 20081125 TO 20081201 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: LABORATORY CORPORATION OF AMERICA HOLDINGS, NORTH CAROLINA Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:040079/0926 Effective date: 20161020 Owner name: CULTIVAN SANDBOX FOOD & AGRICULTURE FUND II, L.P., ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:040079/0926 Effective date: 20161020 Owner name: SILICON VALLEY BANK, CALIFORNIA Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:040074/0453 Effective date: 20161020 Owner name: INTERSOUTH PARTNERS VII, L.P., NORTH CAROLINA Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:040079/0926 Effective date: 20161020 Owner name: SANDBOX ADVANTAGE FUND, L.P., ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:040079/0926 Effective date: 20161020 Owner name: LABORATORY CORPORATION OF AMERICA HOLDINGS, NORTH Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:040079/0926 Effective date: 20161020 Owner name: CULTIVAN SANDBOX FOOD & AGRICULTURE FUND II, L.P., Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:040079/0926 Effective date: 20161020 |
|
AS | Assignment |
Owner name: CULTIVIAN SANDBOX FOOD & AGRICULTURE FUND II, L.P., ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:041834/0684 Effective date: 20170123 Owner name: HANNAN, JTWROS, KAREN LEE AND ROBERT E., SOUTH CAROLINA Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:041834/0684 Effective date: 20170123 Owner name: HANNAN, JTWROS, KAREN LEE AND ROBERT E., SOUTH CAR Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:041834/0684 Effective date: 20170123 Owner name: CULTIVIAN SANDBOX FOOD & AGRICULTURE FUND II, L.P. Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:041834/0684 Effective date: 20170123 Owner name: INTERSOUTH PARTNERS VII, L.P., NORTH CAROLINA Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:041834/0684 Effective date: 20170123 Owner name: GREENBAUM, GARY R., ARIZONA Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:041834/0684 Effective date: 20170123 Owner name: SANDBOX ADVANTAGE FUND, L.P., ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:041834/0684 Effective date: 20170123 Owner name: ORIGAMI CAPITAL PARTNERS, LLC, ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:041834/0684 Effective date: 20170123 |
|
AS | Assignment |
Owner name: INTERSOUTH PARTNERS VII, L.P., NORTH CAROLINA Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:042204/0515 Effective date: 20170501 Owner name: MIDDLELAND AG FUND II, L.P., DISTRICT OF COLUMBIA Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:042204/0515 Effective date: 20170501 Owner name: SANDBOX ADVANTAGE FUND, L.P., ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:042204/0515 Effective date: 20170501 Owner name: CULTIVIAN SANDBOX FOOD & AGRICULTURE FUND II, L.P. Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:042204/0515 Effective date: 20170501 Owner name: ORIGAMI CAPITAL PARTNERS, LLC, ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:042204/0515 Effective date: 20170501 Owner name: CULTIVIAN SANDBOX FOOD & AGRICULTURE FUND II, L.P., ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:ADVANCED ANIMAL DIAGNOSTICS, INC.;REEL/FRAME:042204/0515 Effective date: 20170501 |
|
AS | Assignment |
Owner name: ADVANCED ANIMAL DIAGNOSTICS, INC., NORTH CAROLINA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SILICON VALLEY BANK;REEL/FRAME:047276/0944 Effective date: 20180823 |